You are here: Industry Insights > Chipscreen

News List

Chinese Developed New Drug Exploits the Field of Diabetes PharmaSources/Yi
November 01, 2021
Recently, the marketing application of chiglitazar sodium tablets, a new type 1 drug of Chipscreen (the relevant acceptance No. is CXHS1900032), has entered the administrative examination and approval stage, and it is expected that...
Pharmaceutical News of the Week | CPhI.CN - Performance PharmaSources/Caicai
August 06, 2020
Chipscreen released its 2020 H1 performance report on July 27.
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan prnasia
June 25, 2021
Shenzhen Chipscreen Biosciences' licensing partner, HUYABIO International (HUYABIO™), announced the regulatory approval for Tucidinostat (also known as Chidamide, Epidaza ®, HBI-8000) monotherapy of relapsed or refractory (R/R) adult T-cell ...
Chipscreen, Novogene team up to develop companion diagnostics biospectrumasia
October 09, 2019
Chiauranib is a multi-kinase inhibitor designed and developed by Chipscreen to target several novel molecules in three signaling pathways.
Chipscreen upsizes IPO as investors flock to China's STAR Market fiercepharma
August 04, 2019
Shenzhen Chipscreen Biosciences has upsized its IPO after the shares reserved for individuals were almost 3,000 times oversubscribed.